This research summary describes the major multifocal contact lens (MFCL) research studies for myopia control, and what we still need to learn. From the first studies only a decade ago, to wearing time, commercially available lenses, the influence of BV, novel designs and more, this comprehensive review will get you all the way up to date on MFCLs.
This review covers how well axial length relates to refraction and predicting future myopia, how to measure axial length, its value in orthokeratology and atropine management, how axial length influences a treatment plan and can you practice myopia management without it.
The much anticipated BLINK study has just been published! Hot off the press, we examine the results comparing +1.50 and +2.50 centre distance MFCLs, explain the study and describe how these results compare to other myopia controlling contact lenses.
Professor Karla Zadnik, Dean of the Ohio State University College of Optometry in the USA,, discusses the Childhood Atropine for Myopia Progression (CHAMP) study, engaging with the literature, her favourite papers and an alternative take on myopia control as standard of care.
Atropine can be used for myopia control as a monotherapy or as an adjunct to an optical intervention – we discuss patient selection, atropine combination treatments, how to taper and when to stop.
Most atropine currently prescribed for myopia control is compounded. How could this influence consistency of treatment and research results? What could current research lead to in future prescribing? Read more here.
As there are systemic side effects of atropine eye drops, they could be contraindicated in young patients with some conditions, syndromes, and when taking specific systemic medications. Medication safety is also discussed.
As technology evolves the next big change is likely to be Virtual Reality. Could we expect Virtual Reality to be
When it comes to myopic teenagers and stabilization of their myopia progression, we have some research data available. Studies such
So you have initiated myopia treatment and had a successful control of a rapid progressor’s myopia. When should you stop
